The case for medical treatment in chronic stable coronary artery disease.
Nash
David T
DT
Syracuse Preventive Cardiology, and Department of Medicine, State University of New York at Syracuse, Health Sciences Center, 600 E. Genesee Street, Presidential Plaza Suite 204, Syracuse, NY 13202, USA. davidtnash@aol.com
D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008019:Life Style; D012307:Risk Factors; D040242:Risk Reduction Behavior
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors